Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and ...
Onlymyhealth50m
Breakthrough Schizophrenia Drug Offers Hope with Fewer Side Effects
New schizophrenia drug Cobenfy offers hope with fewer side effects targeting symptoms more effectively than traditional ...
OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2
PRESS RELEASE Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate ...
moneycontrol.com13m
Bristol-Myers Squibb
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...
Pfizer offloads $3.3 billion stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's ...